Robert Foglesong Email & Phone Number

Ongar, Essex, Gb

Selcia is a global contract research provider of 14C radiolabeling services, integrated drug discovery and medicinal chemistry. Established in 2001, Selcia’s two divisions, Selcia Discovery and Selcia Radiolabeling, work in state of the art R+D facilities north east of London (UK). Globally active, Selcia offers a unique range of services to the life sciences community: we have an in-house GLP certified analytical laboratory together with a Good Manufacturing Practice (GMP) certificate for the preparation of 14C labeled APIs operating alongside our integrated drug discovery services.Selcia’s 14C labeling service extends well beyond human health into diverse markets including agrochemicals, animal health, nutrition, cosmetics, flavors and fragrances. Our collaborations and drug discovery ventures span a wide range of organizations, from virtual biotechnology companies to mid-sized pharma and some of the world’s largest pharmaceutical companies. A fully independent organization, we operate with an unusually high degree of freedom allowing us to build innovative and flexible relationships. As the world’s largest independent supplier of custom carbon-14 radiochemicals we have earned a reputation for excellence and success in carrying out the most challenging synthetic projects.For further information or to request a quote please contact me at robert.foglesong@selcia.com

Jersey City, New Jersey, Us

SCYNEXIS seamlessly integrates Medicinal Chemistry, Computational Chemistry, Analytical Chemistry, ADMET-PK and Bioanalytical Chemistry into SCYNEXIS Research Teams that enable our clients to meet very specific, timeline-driven project demands. Our team has the size and experience to handle projects of any complexity. Our scientists have been involved in the selection of multiple candidates across a variety of therapeutic areas in both human and animal health.SCYNEXIS Discovery Research accelerates drug discovery projects by:• Discovering pre-clinical candidates (PCC) to treat important diseases• Providing consultancy on disease target selection and optimization strategy• Incorporating networks of experts and technologies to drive successful drug discovery projects• Offering risk-sharing business models to allow cost-containmentTo support both lead optimization and candidate selection, SCYNEXIS provides rapid generation of reliable ADMET and pharmacokinetic (PK) data for compounds in discovery through pre-IND filing. SCYNEXIS rapidly screens for properties such as metabolic stability, permeability and cytotoxicity to prioritize and differentiate lead series.SCYNEXIS teams are an independently operating extension of your internal research organization.

Jersey City, New Jersey, Us

Responsible for leading multiple client-based drug discovery programs. Leads were discovered and optimized in GPCR, oncology and CNS among others. A program in peripheral pain resulted in initiation of clinical trials

Oversight of a DPP IV program leading to preclinical candidate selection

Indianapolis, Indiana, Us

Group Leader in hit-to-lead activities, lead optimizationTargeted areas including cardiovascular, proteases and protein protein interactionsTechnology advances for efficient preparation of focus lead optimization libraries

Phd, Chemistry

Bs, Chemistry

Post-Doc